[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353376-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353376-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","alkylating-agents-activate-an-slfn11-dependent-vulnerability-that-confers-parp-1-inhibitor-sensitivity-in-kidney-cancer","Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer","","Background PARP inhibitors show substantial clinical benefit, especially in BRCA1/2-mutated tumors, yet clear cell renal cell carcinoma with wild type BRCA1/2 resists PARP inhibitor monotherapy. Methods An in vitro chemical screen identified alkylating agents that synergize with PARP inhibition; sensitivity was assessed by PARP-1 activity and multiple DNA damage and tumor growth assays. Mechanistically, expression profiling and gain- and loss-of-function studies evaluated repair pathway involvement. Results Temozolomide and streptozocin hyperactivate PARP-1 via SLFN11, driving acquired PARP-1 dependency and PARP inhibitor sensitivity while altering BRCA1 and homologous recombination repair. Conclusion SLFN11-dependent vulnerability supports a potential strategy to sensitize BRCA1/2-WT kidney cancers to PARP inhibition.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/alkylating-agents-activate-an-slfn11-dependent-vulnerability-that-confers-parp-1-inhibitor-sensitivity-in-kidney-cancer/353376/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/alkylating-agents-activate-an-slfn11-dependent-vulnerability-that-confers-parp-1-inhibitor-sensitivity-in-kidney-cancer/353376.png","ImageObject",300,407,{"name":42,"@type":43},"OmBimo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are PARP inhibitors less effective for BRCA1/2-WT clear cell renal cell carcinoma?","Question",{"text":63,"@type":64},"BRCA1/2-WT ccRCC shows poor response to single-agent PARP inhibitor treatment in preclinical models, indicating that previously characterized PARP-related sensitivity features are insufficient to confer vulnerability.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were alkylating agents identified as potential PARP sensitizers?",{"text":68,"@type":64},"A chemical screen was performed using in vitro assays to find alkylating agents that synergize with PARP inhibition, followed by evaluation of ccRCC sensitivity using PARP-1 activity measurements and multiple functional assays.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does SLFN11 play in drug sensitivity to PARP inhibitors?",{"text":72,"@type":64},"SLFN11 is selectively upregulated and promotes proteasomal degradation of BRCA1, creating a PARP-1 dependency. When SLFN11 is lost, BRCA1 levels rise, homologous recombination repair increases, and excessive DNA damage after combination treatment is mitigated.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353376,1790194413,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Wang et al. Journal of Experimental & Clinical Cancer Research (2026) 45:176 [https://doi.org/10.1186/s13046-026-03743-1](https://doi.org/10.1186/s13046-026-03743-1)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nAlkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer  \nChenliang Wang1, Ming Zhu1, Lei Bao1, Vanina ToffessiTcheuyap2,3, James Brugarolas2,3, Weibo Luo1,4* and Yingfei Wang1,5,6*  \nAbstract  \nBackground PARP inhibitors have demonstrated notable clinical benefit, particularly in tumors with BRCA1/2 mutations. Clear cell renal cell carcinoma (ccRCC) carrying wild type (WT) BRCA1/2 is resistant to PARP inhibitor monotherapy. Strategies to enhance the sensitivity of BRCA1/2-WT ccRCC to PARP inhibitors remain challenging. Methods An in vitro chemical screen was performed to identify alkylating agents that synergize with PARP inhibition using cell viability assays. ccRCC sensitivity to individual alkylating agents was further assessed by measuring PARP-1 activity. The therapeutic effects of monotherapy and combination treatment with alkylating agents and PARP inhibitors were evaluated through DNA damage repair assays, cell viability assays, colony formation assays, ccRCC cell xenograft assays, and ccRCC patient-derived xenograft assays. Mechanistic insights and DNA repair pathway involvement were assessed using comparative expression profiling and gain-and loss-of-function approaches. Results BRCA1/2-WT ccRCC exhibits markedly higher PARP-1 activity compared to breast cancers. A subset of alkylating agents, including Temozolomide (TMZ) and Streptozocin, is identified to induce hyperactivation of PARP-1, creating a PARP-1 dependency in ccRCC cells that renders these cells sensitive to PARP inhibitors in vitro and in mice. Mechanistically, SLFN11 is selectively upregulated and boosts proteasomal degradation of BRCA1 protein in ccRCC cells. Loss of SLFN11 increases BRCA1 levels and enhances homologous recombination repair, mitigating prolonged excessive DNA damage in ccRCC cells following combination treatment with TMZ and Olaparib. SLFN11 is inversely correlated with BRCA1 expression and potentiates the therapeutic efficacy of TMZ and Olaparib combination treatment in ccRCC patient-derived xenograft models.  \nConclusion Our findings reveal an intrinsic SLFN11-dependent vulnerability in ccRCC that synergizes with alkylating agents to induce an acquired PARP-1 dependency, thereby sensitizing BRCA1/2-WT tumors to PARP inhibition. Therefore, this work uncovers a potential therapeutic strategy for targeting SLFN11-high kidney cancers.  \nKeywords PARP-1, Alkylating agent, PARP inhibitor, ccRCC, SLFN11, BRCA1  \n*Correspondence:  \nWeibo Luo [Weibo.Luo@UTSouthwestern.edu](Weibo.Luo@UTSouthwestern.edu)[ ](Weibo.Luo@UTSouthwestern.edu)Yingfei Wang [Yingfei.Wang@UTSouthwestern.edu](Yingfei.Wang@UTSouthwestern.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.","cbCainu20wWPSaoR","https://ap.wps.com/l/cbCainu20wWPSaoR","pdf",14984049,18,"English","# Background\n## Synthetic lethality and PARP inhibition context\n## Challenges for BRCA1/2-WT ccRCC\n# Methods\n## In vitro chemical screening and viability testing\n## PARP-1 activity and DNA damage repair assays\n## Combination and xenograft evaluation\n## Mechanistic analyses and pathway involvement\n# Results\n## PARP-1 activity and identification of candidate alkylating agents\n## SLFN11 upregulation, BRCA1 degradation, and dependency\n## Impact on homologous recombination repair\n## Correlation in patient-derived xenografts\n# Conclusion","[{\"question\":\"Why are PARP inhibitors less effective for BRCA1/2-WT clear cell renal cell carcinoma?\",\"answer\":\"BRCA1/2-WT ccRCC shows poor response to single-agent PARP inhibitor treatment in preclinical models, indicating that previously characterized PARP-related sensitivity features are insufficient to confer vulnerability.\"},{\"question\":\"How were alkylating agents identified as potential PARP sensitizers?\",\"answer\":\"A chemical screen was performed using in vitro assays to find alkylating agents that synergize with PARP inhibition, followed by evaluation of ccRCC sensitivity using PARP-1 activity measurements and multiple functional assays.\"},{\"question\":\"What role does SLFN11 play in drug sensitivity to PARP inhibitors?\",\"answer\":\"SLFN11 is selectively upregulated and promotes proteasomal degradation of BRCA1, creating a PARP-1 dependency. When SLFN11 is lost, BRCA1 levels rise, homologous recombination repair increases, and excessive DNA damage after combination treatment is mitigated.\"}]","Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer | PDF",1790105000,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7470fca3d9d61cf5c524e81a17404e2c.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7ad4b3f407b8e7470cbfc54bbabc765.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a078aec73d2cc4c094c3ef65b5c60206.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d27fa38be58f302dc9d7a7fd2f8f980b.webp",980,1306]